Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M4,284Revenue (TTM) $M15.0Net Margin (%)-1,334.4Altman Z-Score59.2
Enterprise Value $M4,065EPS (TTM) $-2.3Operating Margin %-1,376.3Piotroski F-Score2
P/E(ttm)--Beneish M-Score-5.4Pre-tax Margin (%)-1,334.4Higher ROA y-yN
Price/Book17.310-y EBITDA Growth Rate %--Quick Ratio10.2Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio10.2Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-51.5Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-58.6Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M88.1ROIC % (ttm)-2,413.3Gross Margin Increase y-yN

Gurus Latest Trades with NBIX

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

NBIX is held by these investors:



NBIX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Grigoriadis Dimitri E.Chief Research Officer 2017-05-23Sell10,000$53.39-8.88view
Lloyd-Smith MalcolmChief Regulatory Officer 2017-05-19Sell9,960$53.63-9.29view
OBrien Christopher FlintChief Medical Officer 2017-05-18Sell105,634$53.32-8.76view
Lippoldt DarinChief Legal Officer 2017-05-18Sell10,000$53.27-8.67view
Nevinny Corinne HDirector 2017-05-05Sell5,000$53.98-9.87view
Grigoriadis Dimitri E.Chief Research Officer 2017-05-02Sell10,000$55-11.55view
GORMAN KEVIN CHARLESCEO 2017-05-02Sell21,739$53.23-8.6view
Gano KyleChief Business Development Off 2017-05-01Sell15,000$54-9.91view
OBrien Christopher FlintChief Medical Officer 2017-04-12Sell13,065$50.42-3.51view
Lloyd-Smith MalcolmChief Regulatory Officer 2017-04-12Sell13,065$50.42-3.51view

Quarterly/Annual Reports about NBIX:

News about NBIX:

Articles On GuruFocus.com
Neurocrine Announces Phase II Results of VMAT2 Inhibitor INGREZZA® For Treatment of Tourette Syndro May 23 2017 
What Drug Approval Means for Neurocrine Biosciences May 19 2017 
Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference May 11 2017 
Neurocrine Biosciences Reports First Quarter 2017 Results May 09 2017 
Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2017 Results May 03 2017 
Neurocrine Biosciences, Inc. Announces Closing of Offering of $517.5 Million of Convertible Senior N May 02 2017 
Neurocrine Biosciences, Inc. Prices $450.0 Million Convertible Senior Notes Offering Apr 26 2017 
Neurocrine Announces Proposed Convertible Senior Notes Offering Apr 25 2017 
Neurocrine Announces INGREZZA™ Long-Term Safety and Efficacy Data to be Presented at the 2017 Amer Apr 21 2017 
Neurocrine Announces FDA Approval of INGREZZA™ (valbenazine) Capsules as the First and Only Approv Apr 11 2017 

More From Other Websites
NBIX: P2 Study in Tourette’s Syndrome Does Not Meet Primary Endpoint; P2b Study to Start Before... May 25 2017
Did Neurocrine Just Leave The Door Open For Teva In Tourette's? May 24 2017
Neurocrine's Phase 2 Disappointment: Why The Company's Down, But Not Out May 24 2017
Industry News And Stocks To Watch May 24 2017
Biotech Movers: Inovio, Neurocrine, Alnylam May 24 2017
Nuerocrine's Tourette's syndrome drug trial fails May 23 2017
Neurocrine Announces Phase II Results of VMAT2 Inhibitor INGREZZA® For Treatment of Tourette... May 23 2017
What Drug Approval Means for Neurocrine Biosciences May 19 2017
Neurocrine Announces INGREZZA® (valbenazine) Capsules Pharmacokinetic Profile and Long-Term Data to... May 18 2017
AbbVie Presents Pivotal Phase 3 Data on Investigational Treatment Elagolix at the World Congress on... May 17 2017
Edited Transcript of NBIX earnings conference call or presentation 9-May-17 9:00pm GMT May 15 2017
NBIX: INGREZZA™ Launch Commences… May 11 2017
Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference May 11 2017
Neurocrine reports 1Q loss May 09 2017
Neurocrine Biosciences Reports First Quarter 2017 Results May 09 2017
Investor Network: Neurocrine Biosciences, Inc. to Host Earnings Call May 09 2017
Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2017 Results May 03 2017
Why Neurocrine is charging twice as much for its new drug as it said it would May 03 2017
Neurocrine Biosciences, Inc. Announces Closing of Offering of $517.5 Million of Convertible Senior... May 02 2017
Neurocrine Biosciences’ new drug may cost patients more than $10,000 a month, twice as much as... May 01 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)